Clinical Trial Update: A Follow-Up Study to WV19432, to Evaluate Long Term Post-Treatment Effects of PEGASYS (Peginterferon Alfa-2a(40KD))in Patients With HBeAg Positive Chronic Hepatitis B [Phase 4]

View source ↗

Summary

Phase 4 follow-up study assessing long-term post-treatment effects of PEGASYS (peginterferon alfa-2a) in patients with HBeAg-positive chronic hepatitis B; resul…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis B

Drugs mentioned

• Pegasys (pegylated interferon alfa-2a)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Hepatitis B, Chronic | Phase 4 | Status: COMPLETED | Results posted: 2016-03-09